Clinical Trial Update: Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor [Phase 2]

View source ↗

Summary

Phase 2 trial update on ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with hematologic malignancies post haploidentical h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• ATIR (donor T-lymphocytes depleted ex vivo of host alloreactive T-cells)

Snippet

Sponsor: Kiadis Pharma | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-01-12